Skip to search formSkip to main contentSkip to account menu

vosaroxin

Known as: 1,4-Dihydro-7-(3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid, Voreloxin 
A small molecule and a naphthyridine analogue with antineoplastic activity. Vosaroxin intercalates into DNA in a site-specific manner and blocks the… 
National Institutes of Health

Related topics

Related topics

5 relations

Narrower (2)

AG 7352SNS-595
NCIt Antineoplastic Agent Terminology

Broader (2)

NaphthyridinesThiazoles

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
TAK-733, a Selective MEK Inhibitor, Enhances Voreloxin-induced Apoptosis in Myeloid Leukemia Cells
Background/Aim: MEK inhibitors are new promising anticancer drugs. The aim of this study was to investigate the effect of the… 
2017
2017
Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome
Vosaroxin is an anti-cancer quinolone-derived DNA topoisomerase II inhibitor. We investigated vosaroxin with decitabine in… 
Review
2016
Review
2016
The safety and efficacy of vosaroxin in patients with first relapsed or refractory acute myeloid leukemia - a critical review
ABSTRACT Introduction: The outcomes of patients with relapsed or refractory acute myeloid leukemia (AML) are dismal, and… 
2015
2015
Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia.
The development of new treatments for older patients with acute myeloid leukemia is an active area, but has met with limited… 
2011
2011
Adaptive design of VALOR, a phase III trial of vosaroxin or placebo in combination with cytarabine for patients with first relapsed or refractory acute myeloid leukemia.
TPS201 Background: Median overall survival (OS) for patients with relapsed or refractory AML remains short (3-6 mos) with current… 
2010
2010
Voreloxin, a first-in-class anticancer quinolone derivative, acts synergistically with cytarabine in vitro and induces bone marrow aplasia in vivo
Main purposeVoreloxin is a first-in-class anticancer quinolone derivative that intercalates DNA and inhibits topoisomerase II… 
2010
2010
Voreloxin single-agent treatment of older patients (60 years or older) with previously untreated acute myeloid leukemia: Final results from a phase II study with three schedules.
6525 Background: Voreloxin, an anticancer quinolone derivative that inhibits topoisomerase II, has demonstrated clinical activity… 
2010
2010
Final results of a phase II pharmacokinetic/pharmacodynamic (PK/PD) study of combination voreloxin and cytarabine in patients with relapsed or refractory acute myeloid leukemia.
6526 Background: Voreloxin (VOR), an anticancer quinolone derivative that inhibits topoisomerase II, is active in ovarian cancer… 
2009
2009
Phase 1b/2 Pharmacokinetic/Pharmacodynamic (PK/PD) Study of Combination Voreloxin and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia Patients.
Abstract 635 Background: Voreloxin is a first-in-class anticancer quinolone derivative (AQD) that intercalates DNA and inhibits… 
2009
2009
A Phase 2 Dose Regimen Optimization Study of Three Schedules of Voreloxin as Single Agent Therapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia.
A PHASE 2 DOSE REGIMEN OPTIMIZATION STUDY OF THREE SCHEDULES OF VORELOXIN AS SINGLE AGENT THERAPY FOR ELDERLY PATIENTS WITH NEWLY… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)